ERCC2 mutation mapping and distribution across tumor types.

Slides:

Advertisements

Similar presentations

PIK3CA gene amplification in glioblastoma and squamous cell carcinoma (SCC) of the lung. PIK3CA gene amplification in glioblastoma and squamous cell carcinoma.

Advertisements

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Volume 69, Issue 3, Pages (March 2016)

Copyright © 2005 American Medical Association. All rights reserved.

Figure 1. Exploring and comparing context-dependent mutational profiles in various cancer types. (A) Mutational profiles of pan-cancer somatic mutations,

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

The cBio Cancer Genomics Portal.

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Volume 69, Issue 3, Pages (March 2016)

Ewing sarcoma tumors acquire somatic aberrancies with treatment.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Genomic alterations in non–small cell lung cancer, breast cancer, and colorectal cancer. Genomic alterations in non–small cell lung cancer, breast cancer,

Cohort Studies (and Skin Cancer) Never Come Alone

Incidence trends for each human papillomavirus-related cancer-type among women in Norway 1953–2015. Incidence trends for each human papillomavirus-related.

Whole-Genome Sequencing Analysis Identifies a Distinctive Mutational Spectrum in an Arsenic-Related Lung Tumor Victor D. Martinez, PhD, Kelsie L. Thu,

Comparison of the nADC value and CNR on T2-weighted images of 26 metastatic brain tumors of different histologic types. Comparison of the nADC value and.

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Pan-Cancer Analysis of Mutation Hotspots in Protein Domains

Separation of colonospheres from differentiated tumor cells by cluster analysis. Separation of colonospheres from differentiated tumor cells by cluster.

The Mucinous Lung Tumor Signature is highly enriched in colorectal, stomach, pancreatic, lung (adenocarcinoma; LUAD), and breast cancers The Mucinous Lung.

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

Cancer mutations in enriched RBP motifs.

Box plot of acquisition times across the various study cohorts.

Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.

NRG1 rearrangements are found in multiple solid tumors.

PCT imaging with ICA reference of a patient with right tongue base squamous cell carcinoma. PCT imaging with ICA reference of a patient with right tongue.

A, PTEN loss signature score in resected SQCLC brain metastases.

Integrated mRNA and microRNA expression and DNA methylation clusters.

Reduced BAI1 expression is associated with breast cancer patient survival. Reduced BAI1 expression is associated with breast cancer patient survival. A,

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

Somatic mutational rates and survival analysis of IBD-CRC.

The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.

Targetable alterations and pathways in TNBCs after NAC

Temporal and spatial dissection of mutation spectra in esophageal adenocarcinoma samples. Temporal and spatial dissection of mutation spectra in esophageal.

Irradiated whole-cell vaccination with MOC1, but not MOC2, induces immunologic memory. Irradiated whole-cell vaccination with MOC1, but not MOC2, induces.

Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level.

MPM cases with GNH. A, WES-based LOH profiling with the FACETS algorithm revealed three MPM samples with genome-wide LOH. B, Allelic copy-number plots.

Heterogeneous effects of fulvestrant were observed between lesions within individuals. Heterogeneous effects of fulvestrant were observed between lesions.

Distribution of FGFR aberrancies in urothelial cancers.

PD-1 expression in ovarian cancer.

Clustering analysis of DTC-associated genes.

The long tail of mutational hotspots in cancer.

Prevalence of germline T790M.

Location of the ER mutations and frequencies per cohort.

Change in FES uptake in the tumor during fulvestrant treatment.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Frequently mutated genes in colorectal cancer.

Molecular definitions of lung adenocarcinoma subtypes.

Gastric, lung, and HPV-related cancer incidence and model fits.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

Cell lines from hematologic cancers, including multiple myeloma (MM), AML, and DLBCL, exhibit a strong dependency on MCL1 for survival. Cell lines from.

Correlations between comutations of HRR-BER or HRR-MMR and tumor mutational burden, neoantigen load, and MSI-H. Correlations between comutations of HRR-BER.

Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

Germline variants influencing primary tumor type.

A, heatmap of copy number alterations determined by array CGH for a panel of 79 frozen NSCLC samples. A, heatmap of copy number alterations determined.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

mRNA expression of PARP1 in SCLC cell lines and solid tumors.

The ovarian cancer cell lines modestly recapitulate the spectrum of mutations found in primary ovarian tumors. The ovarian cancer cell lines modestly recapitulate.

High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.

Driver pathways and key genes in OSCC

CASP8 mutations are associated with fewer CNAs and RAS family mutations. CASP8 mutations are associated with fewer CNAs and RAS family mutations. A, number.

Molecular characterization of esophagogastric tumors.

TME characteristics of TCGA-STAD subtype and cancer somatic genome.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Presentation transcript:

ERCC2 mutation mapping and distribution across tumor types. ERCC2 mutation mapping and distribution across tumor types. A, a stick plot of ERCC2 showing the locations of somatic mutations in the responders compared with ERCC2 mutations observed in two separate unselected bladder cancer exome cohorts. The ERCC2 mutations cluster within or near conserved helicase motifs. B, the somatic ERCC2 mutation frequency in multiple tumor types from TCGA. SCC, squamous cell carcinoma. C, structure of an archaebacterial ERCC2 (PDB code, 3CRV) with mutations identified in the responder cohort mapped to their equivalent position. These locations are shown in the context of canonical germline ERCC2 mutations responsible for XP, XP/Cockayne syndrome (CS), and trichothiodystrophy (TTD). Eliezer M. Van Allen et al. Cancer Discovery 2014;4:1140-1153 ©2014 by American Association for Cancer Research